Cagrilintide and the amylin story — why CagriSema is generating interest
8 min read · Uplevel editorial
For about a decade, obesity pharmacology was a field that kept almost delivering. The compounds that made it through the regulatory process were real drugs with real effects, but the effect sizes were modest by the standard of what the clinical need demanded — five percent body weight, eight percent, numbers that mattered medically but didn't shift the felt experience of treatment from incremental to transformative. Then the GLP-1 receptor agonists arrived at full dose in obesity indications, and the conversation changed. Fifteen to twenty percent body weight reduction in clinical trials was a number that made physicians and patients alike recalibrate their model of what was pharmacologically achievable. The question that immediately followed — among researchers, clinicians, and the industry watching closely — was not whether this was sufficient, but what would come next.
That question is where Cagrilintide enters.
To understand Cagrilintide, you have to understand amylin, and to understand amylin you have to know where it comes from. Your pancreatic beta cells don't just secrete insulin. Every time insulin is released in response to a meal, amylin — also called islet amyloid polypeptide, or IAPP — is co-secreted alongside it, in a roughly fixed ratio. Amylin is not insulin's redundant twin. It does different things, through different mechanisms, in different places in the brain and body. It slows gastric emptying, reducing the rate at which glucose from a meal reaches the bloodstream and smoothing the postprandial glucose spike that rapid gastric transit produces. It suppresses postprandial glucagon secretion — glucagon being the hormone that signals the liver to release glucose, which is exactly what you don't want in excess after a meal. And it acts centrally, through area postrema in the brainstem and hypothalamic circuits, to generate satiety signals that are genuinely distinct from those produced by GLP-1. You feel full after a meal partly because of insulin, partly because of GLP-1, and partly because of amylin, and these signals are not redundant — they reach different receptors through different neural pathways and produce complementary effects.
In type 1 diabetes and advanced type 2 diabetes, beta cells are damaged or destroyed, which means insulin secretion is impaired — and amylin secretion falls away with it. The consequence is a metabolic environment where postprandial glucose management is harder, gastric emptying is inappropriately fast, and one major satiety signal is chronically absent. Pramlintide — the first FDA-approved amylin analog, sold as Symlin — was developed to address exactly this deficit. It was approved for both type 1 and type 2 diabetes as an adjunct to mealtime insulin, and in trials it reduced HbA1c and supported weight loss alongside its glucose management effects. The clinical uptake of pramlintide was limited, however, and the reason is practical rather than mechanistic: it requires injection with each meal, it must be used separately from insulin, and the dosing complexity added real burden to patients who were already managing a complicated regimen. The molecule worked. The logistics worked against it.
Cagrilintide is Novo Nordisk's answer to the logistics problem. It is a long-acting amylin analog — designed with fatty acid side chains that enable binding to albumin in the bloodstream, dramatically extending the half-life and enabling once-weekly subcutaneous dosing. The pharmacokinetic reengineering that transformed semaglutide from a twice-daily oral compound with modest efficacy into a once-weekly injectable with the largest weight-loss effect sizes in obesity pharmacology history is the same conceptual template applied to amylin. You take a mechanism that works and that has limited adoption because of dosing burden, extend the half-life, reduce the injection frequency, and the clinical picture changes.
The mechanism complementarity between GLP-1 agonism and amylin agonism is what makes CagriSema — the combination of Cagrilintide and Semaglutide — theoretically compelling and clinically interesting. GLP-1 receptors are expressed in the vagal afferents and the hypothalamus; they drive satiety, slow gastric emptying, and reduce food intake through circuits that are well-characterized. Amylin receptors — which are calcitonin receptor complexes — are expressed most prominently in the area postrema and the hypothalamus, and they drive satiety through circuits that overlap with but are not identical to GLP-1 pathways. When you combine the two, you are not simply adding a second dose of the same signal; you are hitting two distinct satiety mechanisms simultaneously. Animal models of dual GLP-1 and amylin receptor agonism showed additive and in some cases synergistic reductions in food intake and body weight, and those preclinical results are what drove the combination into clinical development.
The Phase II data for CagriSema generated substantial attention in the field. In the COMBINE 1 trial, participants receiving the highest CagriSema dose achieved approximately 15 percent body weight reduction at 32 weeks — a result that compares favorably to Semaglutide alone at the same timepoint and that, when projected across longer treatment durations typical of obesity trials, suggested endpoint weight loss in the range of Tirzepatide, the dual GIP/GLP-1 agonist that currently represents the high-water mark in approved obesity pharmacology. Tirzepatide's Phase III results showed roughly 20 to 22 percent body weight reduction at 72 weeks; the extrapolated CagriSema trajectory suggests it may reach similar or possibly greater reductions in a longer-duration Phase III program.
The REDEFINE Phase III program is the current stage of CagriSema development. These trials are underway and are evaluating CagriSema in people with obesity, in people with type 2 diabetes, and in people with cardiovascular disease — the same categories where GLP-1 agonists have progressively established their clinical value proposition. The Phase III data is not yet complete and published, which means that any strong claim about CagriSema's ultimate efficacy and safety profile is premature. What Phase II established is proof of mechanism, evidence of meaningful weight loss, and a tolerability profile broadly similar to GLP-1 agonists — nausea, vomiting, gastrointestinal symptoms — without novel safety signals that would derail development. What Phase III will determine is the durability of these effects, the cardiovascular outcome data, and whether the combination's tolerability profile is acceptable at the doses needed to maximize efficacy.
Cagrilintide is investigational. CagriSema is investigational. Neither is FDA-approved as a single product. Cagrilintide alone is not approved. The combination is not approved. This is a compound and a program in active late-stage clinical development, which means it represents the frontier of what is becoming rather than what has arrived. Discussing it in the present tense requires holding that status explicitly.
What CagriSema teaches about the direction of obesity pharmacology is perhaps more important than its specific data. The field is moving toward rational mechanism combination — the deliberate pairing of agents that hit complementary satiety and metabolic pathways, producing effects that exceed what either pathway can produce alone. The GIP/GLP-1 dual agonism of Tirzepatide was the first demonstration of this approach reaching commercial scale. GLP-1/amylin dual agonism with CagriSema is the next. There are others in development: GLP-1/glucagon dual agonists that combine satiety with increased energy expenditure, GLP-1/GIP/glucagon triple agonists that add that third pathway, and amylin/calcitonin combinations exploring different receptor combinations. The common thread is that single-pathway pharmacology appears to have reached something close to its ceiling with semaglutide, and the path to better outcomes runs through combinations that recruit multiple mechanisms simultaneously.
The amylin story specifically has a further implication worth holding. Amylin is co-secreted with insulin in healthy beta cell function — it is not a secondary or minor player in metabolic physiology but a co-regulator that has been overlooked partly because pramlintide's logistics made it seem clinically marginal. Cagrilintide's development is in some sense an act of pharmacological reclamation: restoring a mechanism that was always there and always important, but that previous technology couldn't deliver in a clinically practical form. The lesson for how the field thinks about metabolic disease may extend beyond obesity: if amylin loss in beta cell failure is a meaningful contributor to glycemic dysregulation, then amylin replacement in type 1 and type 2 diabetes may deserve a much larger role than pramlintide's limited adoption suggested. Whether that lesson gets applied depends partly on whether CagriSema's Phase III data is as compelling as Phase II suggested, and partly on whether the clinical community is willing to revisit a mechanism it filed away as impractical.
The next few years of data will be clarifying.
Frequently asked